Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

e chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%. For comparison, published studies using a first-line gemcitabine and platinum-based chemotherapy for advanced NSCLC reported median survivals of 8 to 10.8 months and one-year survival rates of 33% to 43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months for patients treated with paclitaxel and carboplatin chemotherapy alone. Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44%, respectively, at one year and 23% versus 15%, respectively, at two years. - Prostate Cancer Potential Pain Palliation Advantage - increased frequency and duration of pain palliation was observed when adding OGX-011 to either mitoxantrone or docetaxel retreatment as second- line chemotherapy even when compared to the frequency and duration of pain palliation observed in the TAX 327 Study for first-line chemotherapy in patients with CRPC. Durable pain responses defined as a duration of 12 weeks or greater were observed in 44% of evaluable patients in the OGX-011 plus docetaxel retreatment arm and in 38% of patients in the OGX-011 plus mitoxantrone arm. Responses in patients receiving second-line treatment would be expected to be worse than first-line. However, when compared to first-line treatment in the TAX 327 Study, 35% of patients treated with docetaxel had pain responses with a median duration of 3.5 months (not all durations were 12 weeks or greater) and 22% of patients treated with mitoxantrone had pain responses with a median duration of 4.8 mont
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and China Gel Permeation Chromatography (GPC) Industry Report ... The Global and China Gel Permeation Chromatography (GPC) Industry ... current state of the global gel permeation chromatography industry ... report provides a basic overview of the industry including ...
(Date:8/22/2014)... 22, 2014 “Our nation's healthcare ... a national disgrace. Furthermore, every governmental and professional ... current, deplorable state of unorganized dysfunction shares in ... to merely serve as a device to use ... colossal failure(s) that have accumulated through the years ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... Fertilizer Industry” is a professional and in-depth ... The report provides basic Seaweed Fertilizer information, ... industry chain structure as well as industry ... analysis, including domestic market as well as ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Event to focus on nanomedical applications in diagnostics, imaging, and ... ... The Nano-Network, Cleveland Clinic,Lerner Research Institute, and Case Western Reserve ... to,explore the use of nanoparticles for diagnostics, imaging and therapeutics,to improve ...
... Calif., July 8 Arete Therapeutics Inc., a,privately-held ... today announced the appointment of,James Sabry, M.D., Ph.D., ... been a strategic advisor and member of the ... Dinesh Patel in the position of,president and chief ...
... ANN ARBOR, Mich., July 8 NanoBio(R) Corp., ... to prevent and treat infectious diseases, today announced ... board of directors., Dr. Dubin currently serves ... a leading healthcare and biotechnology investment banking firm., ...
Cached Biology Technology:NanoMedicine Summit Returns to Cleveland, September 25-26 2NanoMedicine Summit Returns to Cleveland, September 25-26 3NanoMedicine Summit Returns to Cleveland, September 25-26 4Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer 2Daniel B. Dubin, M.D., Joins NanoBio Corp.'s Board of Directors 2
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... researchers from Beth Israel Deaconess Medical Center (BIDMC ) ... Most Influential Scientific Minds 2014," a comprehensive list ... web resource for science metrics and research performance analysis. ... most influential "are performing and publishing work that their ... science," according to a Thomson Reuters statement. Researchers were ...
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3American Society of Human Genetics 2014 Annual Meeting 2
... mothers are at risk for iron deficiency, which could ... be presented Saturday, April 30, at the Pediatric Academic ... adults, obesity-related inflammation hinders the transport of iron through ... When a woman is pregnant, iron is transferred through ...
... Federal Court of Appeals has overturned an August 2010 ban ... way for broader exploration of how stem cells function and ... of currently incurable diseases. The ruling has been welcomed ... in 2009, and by the nation,s top researchers in the ...
... New Rochelle, NY, April 29, 2011Videoscopy, a ... monthly publication, Journal of Laparoendoscopic & ... by Mary Ann Liebert, Inc., publishers ( ... fully peer-reviewed surgical and microinvasive demonstrations of ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2
Ready-to-use solution....
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: